# FOOTPATH (NCT03487016)

> First-line Therapy in Metastatic PDAC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03487016
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Ludwig-Maximilians - University of Munich
- Conditions: Metastatic Pancreatic Cancer
- Interventions: Gemcitabine; Nab-paclitaxel; 5-FU; Irinotecan Liposomal Injection; Oxaliplatin
- Enrollment: 270
- Primary outcome: Progression-free survival

## Commentary we found

- X threads: 9
- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=footpath-nct03487016

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03487016", "email": "<work email>"}; the inbox owner confirms by the emailed link.